Arcturus Therapeutics (NASDAQ:ARCT) was downgraded by Zacks Investment Research from a "hold" rating to a "sell" rating in a research note issued to investors on Tuesday, Zacks.com reports.
According to Zacks, "Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as Alcobra Ltd, is based in San Diego, CA. "
A number of other equities research analysts also recently issued reports on ARCT. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell increased their price objective on shares of Arcturus Therapeutics from $62.00 to $133.00 in a research note on Monday, December 14th. B. Riley downgraded shares of Arcturus Therapeutics from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $138.00 to $77.00 in a research note on Friday, January 15th. Raymond James downgraded shares of Arcturus Therapeutics from an "outperform" rating to a "market perform" rating and set a $46.00 price objective on the stock. in a research note on Tuesday, December 29th. Roth Capital downgraded shares of Arcturus Therapeutics from a "buy" rating to a "sell" rating and set a $77.00 price objective on the stock. in a research note on Wednesday, December 23rd. Finally, Wells Fargo & Company assumed coverage on shares of Arcturus Therapeutics in a research note on Thursday, January 7th. They set an "overweight" rating and a $118.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and five have assigned a buy rating to the company's stock. The company currently has a consensus rating of "Hold" and an average target price of $68.13.
Shares of ARCT traded down $4.48 during trading hours on Tuesday, hitting $64.96. The company had a trading volume of 44,659 shares, compared to its average volume of 2,552,323. The firm has a market cap of $1.59 billion, a price-to-earnings ratio of -22.40 and a beta of 3.01. The business has a fifty day moving average of $78.62 and a 200-day moving average of $59.77. Arcturus Therapeutics has a 12 month low of $8.51 and a 12 month high of $129.71. The company has a quick ratio of 11.21, a current ratio of 11.21 and a debt-to-equity ratio of 0.06.
Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings results on Saturday, November 14th. The biotechnology company reported ($0.92) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.43). Arcturus Therapeutics had a negative return on equity of 52.32% and a negative net margin of 506.70%. The business had revenue of $2.33 million for the quarter, compared to the consensus estimate of $3.17 million. On average, equities analysts expect that Arcturus Therapeutics will post -3.14 EPS for the current fiscal year.
In related news, Director Ultragenyx Pharmaceutical Inc. sold 442,255 shares of Arcturus Therapeutics stock in a transaction that occurred on Tuesday, December 8th. The shares were sold at an average price of $105.54, for a total transaction of $46,675,592.70. Following the sale, the director now directly owns 2,557,745 shares in the company, valued at approximately $269,944,407.30. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Pad Chivukula sold 10,000 shares of Arcturus Therapeutics stock in a transaction that occurred on Monday, January 4th. The stock was sold at an average price of $46.40, for a total transaction of $464,000.00. Over the last 90 days, insiders sold 462,255 shares of company stock worth $47,692,393. 12.60% of the stock is currently owned by corporate insiders.
Large investors have recently bought and sold shares of the stock. Nisa Investment Advisors LLC acquired a new stake in Arcturus Therapeutics during the 4th quarter worth approximately $43,000. Great West Life Assurance Co. Can bought a new position in Arcturus Therapeutics during the 2nd quarter worth approximately $54,000. Pacer Advisors Inc. bought a new position in Arcturus Therapeutics during the 4th quarter worth approximately $54,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Arcturus Therapeutics by 119.1% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,722 shares of the biotechnology company's stock worth $74,000 after purchasing an additional 936 shares during the last quarter. Finally, Advisor Group Holdings Inc. raised its holdings in Arcturus Therapeutics by 191.2% during the 2nd quarter. Advisor Group Holdings Inc. now owns 1,747 shares of the biotechnology company's stock worth $82,000 after purchasing an additional 1,147 shares during the last quarter. Institutional investors and hedge funds own 74.33% of the company's stock.
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc, an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product; and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA (STARR) technology.
Read More: Limitations to arbitrage trading
Get a free copy of the Zacks research report on Arcturus Therapeutics (ARCT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
15 Energy Stocks Analysts Love the Most
There are more than 450 energy companies traded on public markets. Given the sheer number of pipeline companies, power plant operators, oil and gas production companies, and other energy stocks, it can be hard to identify which energy companies will outperform the market.
Fortunately, Wall Street's brightest minds have already done this for us. Every year, analysts issue approximately 8,000 distinct recommendations for energy companies. Analysts don't always get their "buy" ratings right, but it's worth taking a hard look when several analysts from different brokerages and research firms are giving "strong-buy" and "buy" ratings to the same energy stock.
This slide show lists the 15 energy companies with the highest average analyst recommendations from Wall Street's equities research analysts over the last 12 months.
View the "15 Energy Stocks Analysts Love the Most".